<DOC>
	<DOC>NCT01698931</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare the efficacy of repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy of Repaglinide in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes HbA1c (glycosylated haemoglobin A1c) above 7 % BMI (body mass index) below 32 kg/m^2 FBG (fasting blood glucose) after wash out period 130220 mg/dl Currently treated with diet or OHA (oral hypoglycaemic agent) Current systemic treatment with concomitant medication Known or suspected history of drug or alcohol dependence Any other significant concomitant disease such as cerebrovascular or symptomatic peripheral vascular disease, malignant, disease or severe treated or untreated hypertension Hepatic disease Cardiac problems Active proliferative retinopathy Known or suspected allergy to trial product or related products Women in fertile age and women having the intention of becoming pregnant Body Mass Index (BMI) above 32 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>